Ingenium licenses patents for INGENOtyping platform
German company Ingenium Pharmaceuticals has obtained a license from US company Incyte Genomics under patents directed to animal genetic modification. This license allows Ingenium increased freedom to provide its INGENOtyping technology to pharmaceutical companies and academic institutions in the US. INGENOtyping is a novel method for producing murine models with subtle gene alterations for use in drug discovery and development.
Ingenium's INGENOtyping technology is a high-speed second-generation tool for the in vivo validation of drug targets. It rapidly provides a series of mammalian models that carry unique genetic alterations in any target gene of interest. These models include knockouts as well as more subtle functional alterations, such as increased and reduced gene target activity. The technology is based on a genetically subtle chemical process that generates point mutations in genes and Ingenium's expertise in quickly and reliably producing and analysing mammalian models of disease.
'The value of INGENOtyping is in the breadth of information these models offer,' said Dr Michael C Nehls, ceo of Ingenium. 'We believe this provides a significant benefit in addition to the value of murine knockout models in drug discovery, target validation and drug development.'